The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).
V. Dieras
Honoraria - Amgen
J. Jassem
No relevant relationships to disclose
L. Y. Dirix
No relevant relationships to disclose
J. P. Guastalla
Honoraria - Amgen
P. Bono
No relevant relationships to disclose
S. A. Hurvitz
Honoraria - Roche/Genentech
A. Gonçalves
No relevant relationships to disclose
G. Romieu
No relevant relationships to disclose
S. A. Limentani
Research Funding - Amgen
G. H. M. Jerusalem
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
K. Lakshmaiah
No relevant relationships to disclose
H. H. Roche
Honoraria - Bristol-Myers Squibb
P. Sánchez-Rovira
No relevant relationships to disclose
T. Pienkowski
Honoraria - Roche
Research Funding - Roche
M. A. Seguí-Palmer
No relevant relationships to disclose
A. Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. Sun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. A. Pickett-Gies
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Wildiers
Consultant or Advisory Role - Amgen
Honoraria - Amgen